Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19
| Author | Pouya Safarzadeh Kozani | en |
| Author | Mehdi Sheikhi | en |
| Author | Narges Baharifar | en |
| Author | Setareh Dashti Shokoohi | en |
| Author | Sara Sheikhi | en |
| Author | Seyed Mohamad Javad Mirarefin | en |
| Author | Pooria Safarzadeh Kozani | en |
| Author | Abdolkarim Sheikhi | en |
| Orcid | Pouya Safarzadeh Kozani [0000-0002-2602-3871] | en |
| Orcid | Pooria Safarzadeh Kozani [0000-0002-9901-7851] | en |
| Orcid | Abdolkarim Sheikhi [0000-0002-3559-5548] | en |
| Issued Date | 2022-08-31 | en |
| Abstract | This article does not have an abstract. | en |
| DOI | https://doi.org/10.5812/tms-130706 | en |
| Keyword | COVID-19 | en |
| Keyword | FDA | en |
| Keyword | Monoclonal antibody | en |
| Keyword | Treatment | en |
| Keyword | Bebtelovimab | en |
| Publisher | Brieflands | en |
| Title | Bebtelovimab: The FDA-approved Monoclonal Antibody for Treating Patients with Mild-to-Moderate COVID-19 | en |
| Type | Discussion | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- tms-2-3-130706.pdf
- Size:
- 87.54 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF